Hollencrest Capital Management’s Vincerx Pharma, Inc. Common Stock VINC Stock Holding History

Hollencrest Capital Management’s Portfolio VINC Stock Details VINC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-500	Closed	-$7.16K	–	1235
2024 Q3	$7.16K	Hold	500	–	–	﹤0.01%	812
2024 Q2	$8.1K	Hold	500	–	–	﹤0.01%	771
2024 Q1	$50.6K	Hold	500	–	–	﹤0.01%	487
2023 Q4	$11.8K	Hold	500	–	–	﹤0.01%	706
2023 Q3	$10.1K	Hold	500	–	–	﹤0.01%	724
2023 Q2	$13K	Hold	500	–	–	﹤0.01%	726
2023 Q1	$10.4K	Hold	500	–	–	﹤0.01%	738
2022 Q4	$10.2K	Hold	500	–	–	﹤0.01%	723
2022 Q3	$14K	Hold	500	–	–	﹤0.01%	303
2022 Q2	$13K	Hold	500	–	–	﹤0.01%	333
2022 Q1	$40K	Hold	500	–	–	﹤0.01%	361
2021 Q4	$102K	Buy	+500	New	+$125K	0.01%	355

Other funds holding VINC

SRC

Sage Rhino Capital Menlo Park, California $617M AUM 28.74% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Hollencrest Capital Management's VINC Position: Q4 2024 in Review

Hollencrest Capital Management sold out of Vincerx Pharma, Inc. Common Stock (VINC) in Q4 2024, closing a stake of 500 shares — an estimated $7.16K sold.

Hollencrest Capital Management first reported a position in VINC in Q4 2021 and held it in 12 quarters. The position peaked at $102K in Q4 2021. 22 funds tracked by Wall St. Rank hold VINC as of Q4 2024.

Hollencrest Capital Management reported no remaining Vincerx Pharma, Inc. Common Stock position as of Q4 2024 after selling out during the quarter.
Hollencrest Capital Management sold 500 Vincerx Pharma, Inc. Common Stock shares in Q4 2024, an estimated $7.16K.
Hollencrest Capital Management first reported a position in Vincerx Pharma, Inc. Common Stock in Q4 2021 and held it in 12 quarters.
Hollencrest Capital Management's Vincerx Pharma, Inc. Common Stock position peaked at $102K in Q4 2021.
22 funds tracked by Wall St. Rank held Vincerx Pharma, Inc. Common Stock as of Q4 2024.

Based on Hollencrest Capital Management's 13F filing for Q4 2024, filed 10 Feb 2025.